{"id":"cytarabine-vs-cytarabine-amsacrine-mitoxantrone","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Cardiotoxicity (mitoxantrone-related)"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL2447907","moleculeType":"Unknown","molecularWeight":"1365.63"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cytarabine (ara-C) is a nucleoside analog that is phosphorylated intracellularly and incorporated into DNA, inhibiting DNA polymerase and causing chain termination. Amsacrine and mitoxantrone are topoisomerase II inhibitors that intercalate into DNA and prevent religation of DNA strands, leading to double-strand breaks. The combination therapy targets multiple mechanisms of DNA damage to overcome resistance in acute myeloid leukemia.","oneSentence":"Cytarabine is a cytidine analog that inhibits DNA synthesis, while the combination with amsacrine and mitoxantrone adds topoisomerase II inhibition and intercalating DNA damage to enhance leukemic cell killing.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:31:36.749Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML), particularly in relapsed or refractory disease"}]},"trialDetails":[{"nctId":"NCT00180102","phase":"PHASE4","title":"AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years","status":"COMPLETED","sponsor":"Technische Universität Dresden","startDate":"2003-12","conditions":"Leukemia, Nonlymphocytic, Acute","enrollment":600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone","genericName":"Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone","companyName":"Technische Universität Dresden","companyId":"technische-universit-t-dresden","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cytarabine is a cytidine analog that inhibits DNA synthesis, while the combination with amsacrine and mitoxantrone adds topoisomerase II inhibition and intercalating DNA damage to enhance leukemic cell killing. Used for Acute myeloid leukemia (AML), particularly in relapsed or refractory disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}